Autres langues ORIC Pharmaceuticals, Inc.

Actions

ORIC

US68622P1093

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
13,92 ^USD	+4,04%		+1,38%	+70,17%

03/08	ORIC Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
14/07	ORIC Pharmaceuticals lance un essai de phase 3 pour le rinzimetostat dans le cancer de la prostate métastatique	MT

Autres langues

07/08	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03/08	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/07	ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
14/07	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
14/07	ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
14/07	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone
02/07	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27/05	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04/05	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
04/05	ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
01/05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
17/04	ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
17/04	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings
03/04	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01/04	Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
01/04	Top Premarket Decliners
31/03	ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter
31/03	ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
31/03	ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile
30/03	ORIC Pharmaceuticals to Report Combination Dose Optimization Data from Phase 1b Trial of Rinzimetostat in Patients with mCRPC
27/03	Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer
27/03	ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC